Compositions Comprising Hypsizygus Ulmarius Extract

Abstract

Disclosed are topical compositions comprising extracts of Hypsizygus ulmarius in amounts that are effective to influence LTB4-mediated chemotaxis and/or IL-1β mediated adhesion of polymorphonuclear leukocytes. The Hypsizygus ulmarius extract may be used alone or in combination with secondary anti-inflammatory and skin active agents, such as other mushroom and/or natural extracts. The secondary anti-inflammatory agents may or may not function by antagonizing LTB4-mediated chemotaxis and IL-1β mediated adhesion. The extract may be incorporated into a cosmetically acceptable vehicle. The present invention includes methods of treating skin inflammation by applying to inflamed skin, anti-inflammatory effective amounts of Hypsizygus ulmarius extract in a defined treatment regimen.

1 . A topical anti-inflammatory-specific composition comprising an anti-inflammatory effective amount of  Hypsizygus ulmarius  mycelium extract. 
   
   
       2 . The composition of  claim 1  wherein the anti-inflammatory effect includes inhibition of LTB4 mediated chemotaxis. 
   
   
       3 . The composition of  claim 1  wherein the anti-inflammatory effect includes inhibition of IL-1β mediated adhesion. 
   
   
       4 . The composition of  claim 1  wherein the  Hypsizygus ulmarius  mycelium extract is a 34% ethanolic extract at a concentration of at least 0.1% (w/v) of the total composition. 
   
   
       5 . The composition of  claim 4  wherein the concentration of  Hypsizygus ulmarius  extract is at least 1.0% (w/v) of the total composition. 
   
   
       6 . The composition of  claim 5  wherein the concentration of  Hypsizygus ulmarius  extract is at least 20.0% (w/v) of the total composition. 
   
   
       7 . A topical anti-inflammatory-specific composition comprising an anti-inflammatory effective amount of  Hypsizygus ulmarius  extract, in combination with  Ganoderma lucidum  extract and/or  Cordyceps sinensis  extract. 
   
   
       8 . The composition of  claim 7  wherein the anti-inflammatory effect includes inhibition of LTB4 mediated chemotaxis. 
   
   
       9 . The composition of  claim 7  wherein the anti-inflammatory effect includes inhibition of IL-1β mediated adhesion. 
   
   
       10 . The composition of  claim 7  further comprising one or more of  ocimum sanctum  leaf extract,  silybum marianum  fruit extract, ginger root extract and turmeric root extract. 
   
   
       11 . The composition of  claim 7  wherein the  Hypsizygus ulmarius  extract is a 34% ethanolic extract at a concentration of at least about 0.1% (w/v) of the total composition. 
   
   
       12 . The composition of  claim 11  wherein the concentration of  Hypsizygus ulmarius  extract is at least 1.0% (w/v) of the total composition. 
   
   
       13 . The composition of  claim 12  wherein the concentration of  Hypsizygus ulmarius  extract is at least 20.0% (w/v) of the total composition.